Vor Bio (VOR) announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Most recently, Dr. Sokolove served as Chief Medical Officer In-Residence at Roivant Sciences (ROIV)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study
- Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split
- Vor Biopharma Unveils Promising Phase 3 Trial Results
- Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
- Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint